Should I Buy Sara Medtec Ter SMTI (SMTI)? Finance YouTuber Analysis

The YouTuber is holding Sanara MedTech, acknowledging it's a risky micro-cap and he's currently down. However, he notes that revenue has quadrupled since 2022 and a new product launch next year should re-accelerate growth, making him unwilling to sell now.

“Sara right now is trading at the levels of 2022 while the revenue quadruple, more than quadruple. Next year, they're going to launch a new product that should reacelerate growth. So, okay, this is my riskiest investment. Clearly, it's not going as planned. I'm losing money, but I'm definitely not selling now that the story is finally changing. I'm just going to give it more time. Wait, and let's see.”

This creator is buying SMTI, a micro-cap healthcare company focused on wound care, because his custom 'value ratio' indicator shows it is incredibly cheap, similar to Google. He highlights strong revenue growth (34% last year) and high gross margins (85-90%), expecting valuation to expand as the company approaches profitability. Despite risks like debt and share dilution, he notes the CEO's significant ownership and a new product launch as mitigators.

“I just bought 750 shares for over $20,000. It's a completely unknown ticker you probably never heard. It's a micro cap with a multi-bagger potential that it's currently trading at half its fair value.”